| Autor: |
Broek, Wout W A van den, Berg, Jurriën M ten |
| Předmět: |
|
| Zdroj: |
European Heart Journal; Sep2024, Vol. 45 Issue 33, p3057-3059, 3p |
| Abstrakt: |
The article discusses the use of antiplatelet therapy in patients with acute coronary syndrome (ACS) and the balance between ischaemic and bleeding risks. The standard treatment for ACS involves dual antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor for 12 months. However, this increases the risk of bleeding. Recent studies have explored the use of ticagrelor monotherapy after a short period of DAPT, which has shown a reduction in bleeding rates without an increase in ischaemic events. However, the applicability of these findings to different patient populations and the role of genetic testing in selecting the appropriate antiplatelet therapy remain uncertain. Physicians should evaluate each patient individually to create a personalized antithrombotic strategy. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
